SCHEMBL20135299

SCHEMBL20135299

Cc1cnc(N2CCNC(C)(C)C2)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 1/20 0.39
OGA O60502 1/20 0.37
CSNK1E P49674 1/20 0.36
PRKCQ Q04759 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36
HDAC1 Q13547 1/20 0.35
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 2/20 0.35
PIM1 P11309 2/20 0.35
PIM2 Q9P1W9 2/20 0.35
PIM3 Q86V86 1/20 0.35
BPTF Q12830 1/20 0.34
EIF2AK4 Q9P2K8 1/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29689044 0.99 LATS1 (0.38) LATS1OGACSNK1EPRKCQCDK4
SCHEMBL3397406 0.86 PRKCQ (0.39) LATS1CSNK1EPRKCQCDK4CCND1
SCHEMBL20134764 0.82 ACVR1 (0.41) OGAJAK3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL27741482 0.80 ALDH1A1 (0.43) LATS1PRKCQCDK4CCND1CCND2
SCHEMBL2366129 0.79 TAAR1 (0.47) BPTFCHRNB2CHRNA4HTR1AHTR3A
Hydrochloric Acid SCHEMBL2366927 0.78 TAAR1 (0.46) CHRNB2CHRNA4HTR1AHTR3A
SCHEMBL20468863 0.75 OGA (0.45) OGAPIM1PIM2PIM3
SCHEMBL12991619 0.72 CNR2 (0.50)
SCHEMBL23561133 0.72 CDK4 (0.40) LATS1PRKCQCDK4CCND1CCND2
SCHEMBL29688471 0.72 KIT (0.43) PRKCQPIM1PIM2PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LATS1 4466/4885OGA 933/4885CSNK1E 1039/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LATS1 4304/4885OGA 899/4885CSNK1E 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.